Key result
Various pharmacological modulators affected human stomach myogenic contractions differently, with E-4031 and CaCC blockers influencing contractions but not muscle tone.
A multi-parameter measurement approach identified subtle differences between compounds modulating spontaneous myogenic contractions in human stomach tissue.
Answers are grounded in this paper and cite their sources.
No immediate clinical implications for gastric motility; leaves open targeted ion channel effects on myogenic contractions for mechanistic studies.
Electrical slow waves, generated by interstitial cells of Cajal (ICC), cause spontaneous contractions of human stomach. Software was developed to measure muscle tone and eleven different parameters defining these contractions in human stomach, displaying data as radar plots. A pilot study assessed the effects of potential modulators, selected from among compounds known to influence ICC activity; n = 4–7 each concentration tested/compound. Human distal stomach (corpus-antrum) muscle strips were suspended in tissue baths for measuring myogenic (non-neuronal) contractions in the presence of tetrodotoxin (10-6 M). Initial characterization: Contractions (amplitude 4 ± 0.4mN, frequency 3 ± 0.1 min-1, n = 49) were unchanged by ꭃ-conotoxin GVIA (10-7 M) or indomethacin (10-6 M) but abolished by nifedipine (10-4 M). Carbachol (10-7 M) increased contraction rate and amplitude; 10-6-10-5 M increased tone and caused large, irregular contractions. [Ca2+]i modulators: Ryanodine (10-5-10-4 M) increased muscle tone accompanied by inhibition of myogenic contractions. Xestospongin-C (10-6 M; IP3 channel inhibitor) had no effects. SERCA pump inhibitors, 2-APB and cycloplazonic acid (10-5-10-4 M) increased tone and myogenic contraction amplitude before abolishing contractions; thapsigargin was weakly active. CaCC blockers: MONNA and CaCCinh-A01 had little-or-no effects on tone but reduced myogenic contractions; MONNA (10-4 M) was more effective, reducing amplitude (77.8 ± 15.2%) and frequency. CaV3.1/3.2/3.3 channel block: Mibefradil reduced tone and myogenic contraction amplitude (pIC50 4.8 ± 0.9). Inward-rectifying K+-channel inhibitor: E-4031 (10-4 M) increased contraction duration (17.4 ± 5.8%). Conclusions: (1) Measurement of multiple parameters of myogenic contractions identified subtle differences between compounds, (2) only E-4031 and CaCC blockers influenced myogenic contractions, not muscle tone, (3) studies are needed with compounds with known and/or improved selectivity/potency for human targets affecting ICC functions.
No takes yet. Share an insight, caveat, or question.
Straface et al. (2022) studied Spontaneous myogenic contractions. Pharmacological modulators (e.g., Carbachol, Ryanodine, SERCA pump inhibitors, CaCC blockers, E-4031) was evaluated on Myogenic contractions (amplitude, frequency, tone). Various pharmacological modulators affected human stomach myogenic contractions differently, with E-4031 and CaCC blockers influencing contractions but not muscle tone.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: